Mitratapide

Mitratapide

Systematic (IUPAC) name
2-[(2R)-Butan-2-yl]-4-[4-[4-[4-[[(2S,4R)-2-(4-chlorophenyl)-2-[(4-methyl-1,2,4-triazol-3-yl)sulfanylmethyl]-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one
Clinical data
Trade names	Yarvitan
Pregnancy cat.	?
Legal status	?
Identifiers
CAS number	179602-65-4
ATC code	?
PubChem	CID 213047
Synonyms	Mitratapid; R103757
Chemical data
Formula	C36H41ClN8O4S
Mol. mass	717.28 g/mol

Mitratapide a veterinary drug for the treatment of overweight and obese dogs sold under the brand name Yarvitan. Its mechanism of action involves inhibition of microsomal triglyceride transfer protein (MTP) which is responsible for the absorption of dietary lipids.^[1] Clinical study also suggests that mitratapide may help to reverse insulin resistance in dogs.^[2]

The drug was developed by Janssen Pharmaceutica and is chemically related to the antifungal drugs such as itraconazole which were also developed by Janssen.

References

1. ^ Mitratapide, vetstream.com
2. ^ Dobenecker, B; De Bock, M; Engelen, M; Goossens, L; Scholz, A; Kienzle, E (2009). "Effect of mitratapide on body composition, body measurements and glucose tolerance in obese Beagles". Veterinary research communications 33 (8): 839–47. doi:10.1007/s11259-009-9232-5. PMC 2776940. PMID 19544001. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2776940.